Monopar Therapeutics Inc (MNPR)

Monopar Therapeutics Inc (MNPR) Stock Price & Analysis


MNPR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.81 - $4.88
Previous Close$0.92
Average Volume (3M)30.74K
Market Cap
Enterprise Value$6.40M
Total Cash (Recent Filing)$5.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-1.1
Aug 10, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding10,736,396
10 Day Avg. Volume12,532
30 Day Avg. Volume30,739
Standard Deviation0.21
Financial Highlights & Ratios
Price to Book (P/B)1.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.60
Price Target Upside631.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $0.81 and its highest was $4.88 in the past 12 months.
    What is Monopar Therapeutics Inc’s market cap?
    Currently, no data Available
    When is Monopar Therapeutics Inc’s upcoming earnings report date?
    Monopar Therapeutics Inc’s upcoming earnings report date is Aug 10, 2023 which is in 72 days.
      How were Monopar Therapeutics Inc’s earnings last quarter?
      Monopar Therapeutics Inc released its earnings results on May 11, 2023. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.222 by $0.032.
        Is Monopar Therapeutics Inc overvalued?
        According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Monopar Therapeutics Inc pay dividends?
          Monopar Therapeutics Inc does not currently pay dividends.
          What is Monopar Therapeutics Inc’s EPS estimate?
          Monopar Therapeutics Inc’s EPS estimate is -$0.19.
            How many shares outstanding does Monopar Therapeutics Inc have?
            Monopar Therapeutics Inc has 13,222,056 shares outstanding.
              What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
              Monopar Therapeutics Inc reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.222. Following the earnings report the stock price went down -7%.
                Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
                Currently, no hedge funds are holding shares in MNPR


                Monopar Therapeutics Inc Stock Smart Score

                This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
                Learn more about TipRanks Smart Score

                Company Description

                Monopar Therapeutics Inc

                Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.


                Top 5 ETFs holding MNPR

                Currently, no data available
                Please return soon. This page is being updated.
                Up to five ETFs with an Outperform Smart Score that hold MNPR. The ETFs are listed according to market value of MNPR within the ETF


                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                Acurx Pharmaceuticals
                Eledon Pharmaceuticals
                TRACON Pharmaceuticals
                Applied Molecular Transport

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis